Skip to main content

User account menu

  • My EPI-CE Documentation
  • Log in

Top navigation

  • Contact Us
  • +49 89 416 17270
Bio-Techne Exosome logo

User account menu

  • My EPI-CE Documentation
  • Log in

Main navigation

  • Laboratories
    • ExoDx™ Prostate EPI-CE IVD
  • Physicians
    • ExoDx™ Prostate Test
    • ExoDx™ Prostate Test
    • Challenge of Prostate Cancer
    • Physician FAQs
    • What are Exosomes
    • Publications and Abstracts
  • Patients
    • The ExoDx Prostate Test
    • The ExoDx Prostate Test
    • Understanding PSA Levels
    • About Prostate Cancer
  • Pharma Services
    • Working with Us
    • Biomarker Discovery
    • Assay Development
    • Exosome Enrichment Capabilities
    • Companion Diagnostics (CDx) and Clinical Trial Support
  • Our Technology
    • Our Technology
    • Sensitivity to RNA/DNA
    • Extraction Procedures
    • Superiority to cfDNA and CTCs
  • News & Resources
    • Press
    • Webinars
    • Events

Top navigation

  • Contact Us
  • +49 89 416 17270

Press

  • Bio-Techne To Acquire Exosome Diagnostics, Inc.

    Press Jun 25, 2018

  • Exosome Diagnostics Achieves ISO 13485:2016 Certification

    Press Jun 13, 2018

  • Exosome Diagnostics Announces Bladder Cancer Surveillance Panel

    Press May 22, 2018

  • Exosome Diagnostics’ Second Prospective Validation Study of EPI to be Highlighted at American Urological Association (AUA) Annual Meeting Press Briefing in San Francisco, CA

    Press May 17, 2018

  • Exosome Diagnostics Presents Breakthrough Data Highlighting Tumor Derived RNA in Biofluids at the International Society for Extracellular Vesicles in Spain

    Press May 15, 2018

  • Exosome Diagnostics Continues to Expand Coverage Reach for its EPI Test

    Press May 09, 2018

  • Exosome Diagnostics Expands National Sales Team after Blockbuster Quarter with its Flagship Diagnostic, ExoDx Prostate®(IntelliScore) (EPI) Test

    Press May 08, 2018

  • Exosome Diagnostics Obviates Tissue Biopsies

    Press Apr 17, 2018

  • Exosome Diagnostics Announces Publication of a Highly Sensitive Exosome Based Liquid Biopsy Test for EGFR T790M Mutations in Plasma from Non-Small Cell Lung Cancer Patients

    Press Mar 20, 2018

Pagination

  • First page « First
  • Previous page ‹ Previous
  • Page 1
  • Page 2
  • Current page 3
  • Page 4
  • Next page Next ›
  • Last page Last »

+49 89 416 17270
exosomedx.info@bio-techne.com
Exosome Diagnostics GmbH
Am Klopferspitz 19a
82152 Martinsried
Germany

Footer menu

  • About Bio-Techne
  • Management Team
  • Careers
  • Investors
  • Corporate Responsibility
  • Accreditation and Licensure

Social navigation

  • Facebook
  • Twitter
  • LinkedIn

Iso LogoThe EPI-CE test was developed by Exosome Diagnostics, Inc. according to the European Union directive for in-vitro diagnostic devices IVDD (98/79/EC) and the performance characteristics determined by Exosome Diagnostics, Inc. The test performance has been verified in Exosome Diagnostics GmbH's clinical laboratories in Martinsried, Germany. Exosome Diagnostics GmbH is accredited by Dakks to ISO 15189. Exosome Diagnostics and ExoDx are registered trademarks of Exosome Diagnostics, Inc.

© 2025 ExoDx

Bottom footer navigation

  • Privacy Policy
  • Datanschutzerklärung
  • Impressum